Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD LTE: TEV-48574 in Ulcerative Colitis or Crohn's Disease
NCT05668013Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 2 trial of duvakitug in ulcerative colitis (UC), Crohn's disease, sponsored by Teva Pharmaceutical Industries Ltd.. Started Jan 2023; status: active, not recruiting.
02
Drugs
duvakitug
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05668013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668013.